BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, Ms. Nan Wang, Interim Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to attend four upcoming investor conferences in New York City and Boston.
About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against hand, foot & mouth disease), mumps, rubella, HIB, epidemic meningitis, varicella and human rabies. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, which is anticipated to be launched in 2011.
Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: firstname.lastname@example.org Investors:Stephanie CarringtonThe Ruth GroupTel: +1-646-536-7017Email: email@example.comMedia:Victoria AguiarThe Ruth GroupTel: +1-646-536-7013Email: firstname.lastname@example.org
|SOURCE Sinovac Biotech Ltd.|
Copyright©2010 PR Newswire.
All rights reserved